Abstract
The pharmacokinetics of bucindolol and its major metabolite, 5-hydroxybucindolol, have been studied in eight patients with mild/moderate hypertension. The mean terminal elimination half-life of bucindolol following acute oral dosing was 8.0 +/- 4.5 h, while the elimination half-life of the metabolite was 0.15 +/- 0.13 h. Because of the large intraindividual variation in the pharmacokinetics of the drug and metabolite, no significant differences in the kinetics following acute or chronic dosing were seen. There was very wide interindividual variability in the pharmacokinetics of bucindolol and 5-hydroxybucindolol, and large interindividual differences in the metabolic profiles as assessed by the areas under drug and metabolite concentration-time curves. This latter observation might be associated with a genetic polymorphism of drug metabolism.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Xenobiotica; the fate of foreign compounds in biological systems
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
